43.83
price up icon0.00%   0.00
after-market Handel nachbörslich: 43.78 -0.05 -0.11%
loading
Schlusskurs vom Vortag:
$43.83
Offen:
$43.93
24-Stunden-Volumen:
10.10M
Relative Volume:
0.73
Marktkapitalisierung:
$89.21B
Einnahmen:
$47.70B
Nettoeinkommen (Verlust:
$5.07B
KGV:
17.68
EPS:
2.4784
Netto-Cashflow:
$14.58B
1W Leistung:
+0.46%
1M Leistung:
-0.75%
6M Leistung:
-9.98%
1J Leistung:
-17.18%
1-Tages-Spanne:
Value
$43.58
$43.94
1-Wochen-Bereich:
Value
$43.34
$45.23
52-Wochen-Spanne:
Value
$42.96
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Firmenname
Bristol Myers Squibb Co
Name
Telefon
(609) 252-4621
Name
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Mitarbeiter
34,100
Name
Twitter
@BMSNEWS
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BMY's Discussions on Twitter

Vergleichen Sie BMY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
43.83 89.21B 47.70B 5.07B 14.58B 2.4784
Drug Manufacturers - General icon
LLY
Lilly Eli Co
825.45 736.03B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
190.40 463.72B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.99 403.22B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.36 254.84B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.49 217.76B 63.43B 16.42B 14.72B 6.4861

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-05 Herabstufung Daiwa Securities Outperform → Neutral
2025-04-22 Eingeleitet Cantor Fitzgerald Neutral
2025-04-22 Eingeleitet Piper Sandler Overweight
2024-12-16 Hochstufung Jefferies Hold → Buy
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-13 Hochstufung Daiwa Securities Neutral → Outperform
2024-11-12 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-25 Herabstufung Citigroup Buy → Neutral
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-07-29 Herabstufung Barclays Overweight → Equal Weight
2024-03-11 Herabstufung Societe Generale Buy → Hold
2024-02-06 Herabstufung Redburn Atlantic Buy → Neutral
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-11-15 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-11-02 Herabstufung Daiwa Securities Outperform → Neutral
2023-10-27 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-10-27 Hochstufung HSBC Securities Reduce → Hold
2023-10-27 Herabstufung William Blair Outperform → Mkt Perform
2023-10-20 Fortgesetzt UBS Neutral
2023-07-14 Eingeleitet HSBC Securities Reduce
2023-07-10 Eingeleitet SVB Securities Market Perform
2023-06-28 Eingeleitet Daiwa Securities Outperform
2023-03-06 Eingeleitet Jefferies Hold
2023-01-17 Eingeleitet Cantor Fitzgerald Overweight
2022-11-18 Eingeleitet Credit Suisse Neutral
2022-10-10 Herabstufung Guggenheim Buy → Neutral
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-06-03 Herabstufung Raymond James Outperform → Mkt Perform
2022-04-06 Fortgesetzt Morgan Stanley Underweight
2021-12-17 Eingeleitet Goldman Buy
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-11-01 Herabstufung Argus Buy → Hold
2021-07-27 Fortgesetzt Truist Buy
2021-04-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-04-13 Hochstufung Truist Hold → Buy
2020-11-16 Hochstufung Societe Generale Hold → Buy
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-11-06 Herabstufung Gabelli & Co Buy → Hold
2020-10-19 Hochstufung Guggenheim Neutral → Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-07-28 Eingeleitet Raymond James Outperform
2020-04-02 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-23 Herabstufung Societe Generale Buy → Hold
2020-02-27 Eingeleitet Barclays Equal Weight
2020-01-06 Fortgesetzt Citigroup Buy
2019-12-13 Hochstufung Argus Hold → Buy
2019-11-22 Fortgesetzt Morgan Stanley Equal-Weight
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-08-14 Hochstufung Atlantic Equities Neutral → Overweight
2019-05-28 Eingeleitet Goldman Buy
2019-05-20 Herabstufung Argus Buy → Hold
2019-05-03 Hochstufung Barclays Equal Weight → Overweight
2019-05-03 Fortgesetzt JP Morgan Overweight
2019-01-15 Hochstufung Societe Generale Sell → Buy
2018-10-22 Herabstufung Citigroup Buy → Neutral
Alle ansehen

Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten

pulisher
Oct 26, 2025

Why Bristol Myers Squibb Company Equity Right stock is popular among millennialsRecession Risk & Verified High Yield Trade Plans - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

How high can Bristol Myers Squibb Company stock goEarnings Recap Summary & Consistent Return Investment Signals - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

Visualizing Bristol Myers Squibb Company stock with heatmaps2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

Bristol Myers (BMY) Reports Promising Results from Phase 1 Study in Autoimmune Diseases - GuruFocus

Oct 26, 2025
pulisher
Oct 26, 2025

Will Bristol Myers Squibb Company (BRM) stock beat growth indexesNew Guidance & Free Expert Approved Momentum Trade Ideas - newser.com

Oct 26, 2025
pulisher
Oct 25, 2025

How Bristol Myers Squibb Company Celegne Contingent stock trades under stagflationJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Bristol Myers Squibb reports positive early results from CAR T therapy trial - Investing.com

Oct 25, 2025
pulisher
Oct 25, 2025

Bristol Myers Squibb (NYSE: BMY) shares Phase 1 CD19 CAR T in 71 autoimmune patients - Stock Titan

Oct 25, 2025
pulisher
Oct 25, 2025

BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 (BMYMP.US) is scheduled to release its earnings report before the market opens on October 30. - 富途牛牛

Oct 25, 2025
pulisher
Oct 24, 2025

Applying chart zones and confluence areas to Bristol Myers Squibb CompanyJuly 2025 Highlights & Safe Swing Trade Setup Alerts - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - The Globe and Mail

Oct 24, 2025
pulisher
Oct 24, 2025

Is Bristol Myers Squibb Company stock resilient to inflationPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com

Oct 24, 2025
pulisher
Oct 23, 2025

Analyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Risk adjusted return profile for Bristol Myers Squibb Company Equity Right analyzedPortfolio Profit Report & AI Enhanced Trading Alerts - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Forecasting Bristol Myers Squibb Company Equity Right price range with options dataMarket Volume Summary & Fast Exit/Entry Strategy Plans - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Will Bristol Myers Squibb Company stock deliver better than expected guidanceTrade Risk Summary & Low Drawdown Trading Strategies - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Can Bristol-Myers Squibb’s Innovation Push Reverse Its Stock Slide? - AD HOC NEWS

Oct 23, 2025
pulisher
Oct 23, 2025

Is Bristol Myers Squibb Company (BRM) stock cheap vs fundamentalsJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Bristol-Myers $450M Payment Dispute Heads To Arbitration - Law360

Oct 22, 2025
pulisher
Oct 22, 2025

Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks - The Motley Fool

Oct 22, 2025
pulisher
Oct 21, 2025

Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

Trend analysis for Bristol Myers Squibb Company this week2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

The Play On Bristol-Myers Squibb (NYSE:BMY) - Seeking Alpha

Oct 21, 2025
pulisher
Oct 21, 2025

Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock - Insider Monkey

Oct 21, 2025
pulisher
Oct 21, 2025

Small Cell Lung Cancer Market Research 2025-2035: Growth Driven by Advancements in Novel Therapies, Including Immunotherapies, Targeted Therapies, and Combination Treatments - GlobeNewswire Inc.

Oct 21, 2025
pulisher
Oct 20, 2025

Will Bristol Myers Squibb Company Celegne Contingent stock benefit from Fed rate cuts2025 Technical Overview & High Accuracy Swing Entry Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Bristol-Myers’ $450 Million Earnout Pay Fight Sent to Arbitrator - Bloomberg Law News

Oct 20, 2025
pulisher
Oct 20, 2025

US CBO says orphan drug exemption could add $6 billion to cost of Trump's 'Big Beautiful Bill' - Reuters

Oct 20, 2025
pulisher
Oct 20, 2025

Can Bristol-Myers Squibb Stock Recover After Steep Decline? - AD HOC NEWS

Oct 20, 2025
pulisher
Oct 20, 2025

Bristol-Myers Squibb (BMY) Investor Outlook: Navigating a 21.59% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews

Oct 20, 2025
pulisher
Oct 18, 2025

Can Bristol Myers Squibb Company stock hit record highs againMarket Performance Recap & Expert Verified Movement Alerts - newser.com

Oct 18, 2025
pulisher
Oct 17, 2025

Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Resul - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb, SystImmune report data from lung cancer trial - Seeking Alpha

Oct 17, 2025
pulisher
Oct 17, 2025

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Is Bristol Myers Squibb Company Equity Right building a consolidation baseMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com

Oct 17, 2025
pulisher
Oct 16, 2025

Does Bristol Myers Stock Offer Value as AI Data-Sharing Alliance Makes Headlines? - simplywall.st

Oct 16, 2025
pulisher
Oct 16, 2025

insitro and Bristol Myers Squibb (BMY) Advance ALS Research with New AI-Powered Collaboration - Yahoo Finance

Oct 16, 2025
pulisher
Oct 15, 2025

Bristol Myers Squibb Launches Kopozgo (Mavacamten) In IndiaStatement - TradingView

Oct 15, 2025
pulisher
Oct 15, 2025

What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga

Oct 15, 2025
pulisher
Oct 15, 2025

Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Orbital Therapeutics Deal - Insider Monkey

Oct 15, 2025
pulisher
Oct 15, 2025

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace

Oct 15, 2025
pulisher
Oct 14, 2025

insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com

Oct 14, 2025
pulisher
Oct 14, 2025

insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com Australia

Oct 14, 2025
pulisher
Oct 14, 2025

BMY Collaboration Advances ALS Treatment Development - GuruFocus

Oct 14, 2025
pulisher
Oct 14, 2025

$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers Squibb describes new FAK degradation inducers - BioWorld MedTech

Oct 14, 2025
pulisher
Oct 14, 2025

11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review

Oct 14, 2025

Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general SNY
$51.64
price up icon 4.28%
drug_manufacturers_general PFE
$24.76
price up icon 0.36%
$120.94
price up icon 0.17%
$291.76
price down icon 0.39%
drug_manufacturers_general NVO
$52.96
price down icon 0.51%
drug_manufacturers_general MRK
$87.49
price up icon 0.36%
Kapitalisierung:     |  Volumen (24h):